DS
EVLO

David Shaw’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

David Shaw’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-960
Closed -$41K – 5685
2022
Q2 		$41K Sell
960
-187
-16% -$8.67K ﹤0.01% 4878
2022
Q1 		$78K Buy
+1,147
New +$95.5K ﹤0.01% 5049
2021
Q3 		– Sell
-1,689
Closed -$464K – 5370
2021
Q2 		$464K Buy
+1,689
New +$426K ﹤0.01% 4073

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's EVLO Position: Q3 2022 in Review

David Shaw sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2022, closing a stake of 960 shares — an estimated $41K sold.

David Shaw first reported a position in EVLO in Q2 2021 and held it in 3 quarters. The position peaked at $464K in Q2 2021. 41 funds tracked by Wall St. Rank hold EVLO as of Q3 2022.

  • David Shaw reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • David Shaw sold 960 Evelo Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $41K.
  • David Shaw first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • David Shaw's Evelo Biosciences, Inc. Common Stock position peaked at $464K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.